A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol
1 School of Health Sciences, Swinburne University, Hawthorn, Victoria 3122, Australia
2 Monash Alfred Psychiatry Research Centre, Melbourne, Victoria 3004, Australia
3 Department of Psychiatry, Monash University, Clayton, Victoria 3800, Australia
4 School of Psychological Science, La Trobe University, Melbourne, Victoria 3086, Australia
5 Department of Psychiatry, University of Melbourne, Parkville, Victoria 3052, Australia
6 St Vincent’s Hospital Mental Health, Fitzroy, Victoria 3065, Australia
7 Office of the Vice-Chancellor and Discipline of Psychiatry, Monash University, Clayton, Victoria 3800, Australia
8 Department of Psychiatry, University of Melbourne, Parkville, Victoria 3010, Australia
9 Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia
10 Department of Psychology, University of Nevada, Reno, Nevada 89557, USA
11 NorthWestern Mental Health, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia
BMC Psychiatry 2014, 14:198 doi:10.1186/1471-244X-14-198Published: 11 July 2014
Cognitive behavior therapy for psychosis has been a prominent intervention in the psychological treatment of psychosis. It is, however, a challenging therapy to deliver and, in the context of increasingly rigorous trials, recent reviews have tempered initial enthusiasm about its effectiveness in improving clinical outcomes. Acceptance and commitment therapy shows promise as a briefer, more easily implemented therapy but has not yet been rigorously evaluated in the context of psychosis. The purpose of this trial is to evaluate whether Acceptance and Commitment Therapy could reduce the distress and disability associated with psychotic symptoms in a sample of community-residing patients with chronic medication-resistant symptoms.
This is a single (rater)-blind multi-centre randomised controlled trial comparing Acceptance and Commitment Therapy with an active comparison condition, Befriending. Eligible participants have current residual hallucinations or delusions with associated distress or disability which have been present continuously over the past six months despite therapeutic doses of antipsychotic medication. Following baseline assessment, participants are randomly allocated to treatment condition with blinded, post-treatment assessments conducted at the end of treatment and at 6 months follow-up. The primary outcome is overall mental state as measured using the Positive and Negative Syndrome Scale. Secondary outcomes include preoccupation, conviction, distress and disruption to life associated with symptoms as measured by the Psychotic Symptom Rating Scales, as well as social functioning and service utilisation. The main analyses will be by intention-to-treat using mixed-model repeated measures with non-parametric methods employed if required. The model of change underpinning ACT will be tested using mediation analyses.
This protocol describes the first randomised controlled trial of Acceptance and commitment therapy in chronic medication-resistant psychosis with an active comparison condition. The rigor of the design will provide an important test of its action and efficacy in this population.
Australian New Zealand Clinical Trials Registry: ACTRN12608000210370. Date registered: 18 April 2008